Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| electroCore, Inc.ECOR · Entity 6900 | Director | September 02, 2025 | September 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
electroCore, Inc.
Report date September 02, 2025 · Filed September 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,782 |
Reported balance
After 2025-09-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-02 · Grant · Acquired 19,011 · Balance 102,782 F1: Annual Deferred Stock Units award which vests in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. F2: Includes 52,054 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Deferred Stock Units award which vests in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date.
F2: Includes 52,054 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CAS MEDICAL SYSTEMS INC
Report date April 18, 2019 · Filed April 22, 2019
Section 16 reporting ended · disclosed 2019-04-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-04-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-18 · Disposition to issuer · Disposed 930,889 · Balance 150,000 F1: Each issued and outstanding share of common stock was, as a result of the consummation of the merger contemplated by the Agreement and Merger by and among CAS Medical Systems, Inc., Edwards Lifesciences Holding, Inc. and Crown Merger Sub, Inc., dated as of February 11, 2019 (the "Merger Agreement"), canceled in exchange for the right to receive a per share amount equal to $2.45 in cash without interest. Row 2 · 2019-04-18 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: These restricted shares were, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled on April 18, 2019 for no consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2020-08-27 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-18 · Disposition to issuer · Disposed 350,000 · Balance 0 F3: This option, which vested in equal monthly installments over a four year period commencing on August 27, 2010, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2021-12-08 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-18 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: This option, which vested in four equal annual installments commencing on December 8, 2011, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2022-12-17 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-18 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: This option, which vested in four equal annual installments commencing on December 17, 2012, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2023-12-16 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-18 · Disposition to issuer · Disposed 100,000 · Balance 0 F6: This option, which vested in four equal annual installments commencing on December 16, 2014, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2024-12-18 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-18 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This option, which vested in four equal annual installments commencing on December 18, 2015, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2027-12-21 | Direct | 0 |
Reported balance
After 2019-04-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-04-18 · Disposition to issuer · Disposed 60,000 · Balance 0 F8: This option, which vested in four equal annual installments commencing on December 21, 2018, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Each issued and outstanding share of common stock was, as a result of the consummation of the merger contemplated by the Agreement and Merger by and among CAS Medical Systems, Inc., Edwards Lifesciences Holding, Inc. and Crown Merger Sub, Inc., dated as of February 11, 2019 (the "Merger Agreement"), canceled in exchange for the right to receive a per share amount equal to $2.45 in cash without interest.
F2: These restricted shares were, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled on April 18, 2019 for no consideration.
F3: This option, which vested in equal monthly installments over a four year period commencing on August 27, 2010, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
F4: This option, which vested in four equal annual installments commencing on December 8, 2011, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
F5: This option, which vested in four equal annual installments commencing on December 17, 2012, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
F6: This option, which vested in four equal annual installments commencing on December 16, 2014, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
F7: This option, which vested in four equal annual installments commencing on December 18, 2015, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
F8: This option, which vested in four equal annual installments commencing on December 21, 2018, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option.
MISONIX INC
Report date October 29, 2021 · Filed December 08, 2021
Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-29 transaction · row 1
1 source rowRow 1 · 2021-10-29 · Disposition to issuer · Disposed 104,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3: Includes 97,500 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").
F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.
F3: Includes 97,500 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 4, 2025 20:05 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 19,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-012632 · ownership.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,782 F1 · shares: Annual Deferred Stock Units award which vests in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. F2 · balance_after: Includes 52,054 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 01:30 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 16,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-001091 · e663867_4-patton.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,771 F1 · shares: Represents a grant of Deferred Stock Units as a part of an annual director award which vest in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. F2 · balance_after: Includes 12,967 shares that have vested pursuant to previously issued Restricted Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. F3 · balance_after: Includes 35,471 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 12:31 UTC | electroCore, Inc. ECOR · Entity 6900 | PurchaseWarrants to Purchase Common Stock · Derivative | 3,850 | $0.06 Strike: $6.43 | $240.63 |
DisclosureSEC source: 0001193805-24-000756 · e663687_4-patton.xml · derivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,850 Underlying: Common Stock · 3,850 shares Expires 2029-06-05 F1 · kind: On June 5, 2024, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 7,701 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $6.4925 per Unit, inclusive of $6.43 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is immediately exercisable from the date of issuance at an exercise price of $6.43 per share, and expires five years after issuance. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 12:31 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 7,701 | $6.43 | $49,517.43 |
DisclosureSEC source: 0001193805-24-000756 · e663687_4-patton.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,188 F1 · shares: On June 5, 2024, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 7,701 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $6.4925 per Unit, inclusive of $6.43 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is immediately exercisable from the date of issuance at an exercise price of $6.43 per share, and expires five years after issuance. F2 · balance_after: Includes 12,967 shares that have vested pursuant to previously issued Restricted Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. F3 · balance_after: Includes 31,848 shares that have vested pursuant to previously issued Deferred Stock Units; 3,623 of such shares will vest monthly through August 4, 2024, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. All such vested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 13:11 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 21,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-23-001128 · e618856_4-patton.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,487 F1 · shares: Represents a grant of Deferred Stock Units as a part of an annual director award which vest in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting on or after January 1, 2024, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. F2 · balance_after: Includes 12,967 shares that have vested pursuant to previously issued Restricted Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. F3 · balance_after: Includes 13,732 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 14:45 UTC | electroCore, Inc. ECOR · Entity 6900 | PurchaseWarrants to Purchase Common Stock · Derivative | 5,524 | $0.06 Strike: $4.35 | $345.25 |
DisclosureSEC source: 0001193805-23-001086 · e618832_4-patton.xml · derivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,524 Underlying: Common Stock · 5,524 shares Expires 2029-02-02 F1 · kind: On August 2, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 11,049 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $4.4125 per Unit, inclusive of $4.35 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is exercisable beginning six months from the date of issuance at an exercise price of $4.35 per share, and expires five years from the initial exercise date. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 14:45 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 11,049 | $4.35 | $48,063.15 |
DisclosureSEC source: 0001193805-23-001086 · e618832_4-patton.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,748 F1 · shares: On August 2, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 11,049 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $4.4125 per Unit, inclusive of $4.35 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is exercisable beginning six months from the date of issuance at an exercise price of $4.35 per share, and expires five years from the initial exercise date. F2 · balance_after: Includes 12,967 shares that have vested pursuant to previously issued Restricted Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. F3 · balance_after: Includes 13,732 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:31 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 205,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-22-001658 · e618088_4-patton.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,497 F1 · shares: Represents a grant of Deferred Stock Units as a part of an annual director award which vest in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting on or after January 1, 2023, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. F2 · balance_after: Includes 182,000 shares that have vested pursuant to previously issued Restricted Stock Units; 12,500 of shares will vest monthly through April 2, 2023. All such vested and unvested shares were previously reported on Form 4 filings at the time of grant. Read SEC document |
| October 29, 2021 Filed Dec 8, 2021 16:53 UTC | MISONIX INC MSON · Entity 132701 | Disposition to issuerCommon Stock | 104,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-030851 · ownership.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2 · shares: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3 · shares: Includes 97,500 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3 · price: Includes 97,500 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:30 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $22.18 | $0.00 |
DisclosureSEC source: 0001493152-21-016057 · ownership.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-29 F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest on June 30, 2022. Read SEC document |
| June 11, 2021 Filed Jun 16, 2021 00:11 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantRestricted Stock Units · Derivative | 44,510 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-014488 · ownership.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,510 Underlying: Common Stock · 44,510 shares Expires 2031-06-11 F1 · derivative.exercise_date: The Restricted Stock Units vest in 12 equal monthly installments from the grant date; provided, however, that the Restricted Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting on or after January 1, 2022, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 13:44 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 3,060 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001493152-20-012461 · ownership.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060 Underlying: Common Stock · 3,060 shares Expires 2030-06-29 F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest on June 30, 2021. Read SEC document |
| May 14, 2020 Filed May 20, 2020 16:23 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 11,940 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001213900-20-013115 · ownership.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 Underlying: Common Stock · 11,940 shares Expires 2030-05-13 F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest on May 13, 2021. Read SEC document |
| April 02, 2020 Filed Apr 7, 2020 00:03 UTC | electroCore, Inc. ECOR · Entity 6900 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010352 · doc4.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents an award of restricted stock units. The restricted stock units vest (i) in 36 equal monthly increments over a period of 36 months from the grant date, and (ii) in full on the date immediately prior to a change of control, in each case provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 15:23 UTC | MISONIX INC MSON · Entity 132701 | PurchaseCommon Stock | 2,000 | $12.20 | $24,400.00 |
DisclosureSEC source: 0001213900-20-005724 · ownership.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 17:32 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001213900-19-024782 · ownership.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in four equal annual installments on the anniversary of the grant date, November 22, 2019. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 60,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 8 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2027-12-21 F8 · derivative.exercise_date: This option, which vested in four equal annual installments commencing on December 21, 2018, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 100,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 7 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2024-12-18 F7 · derivative.exercise_date: This option, which vested in four equal annual installments commencing on December 18, 2015, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 100,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 6 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2023-12-16 F6 · derivative.exercise_date: This option, which vested in four equal annual installments commencing on December 16, 2014, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 100,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 5 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2022-12-17 F5 · derivative.exercise_date: This option, which vested in four equal annual installments commencing on December 17, 2012, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 100,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 4 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-12-08 F4 · derivative.exercise_date: This option, which vested in four equal annual installments commencing on December 8, 2011, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerStock Option · Derivative | 350,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · derivative · entry 3 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2020-08-27 F3 · derivative.exercise_date: This option, which vested in equal monthly installments over a four year period commencing on August 27, 2010, was, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · nonDerivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: These restricted shares were, as a result of the consummation of the merger contemplated by the Merger Agreement, canceled on April 18, 2019 for no consideration. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 10:31 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | Disposition to issuerCommon Stock | 930,889 | $2.45 | $2,280,678.05 |
DisclosureSEC source: 0001449374-19-000013 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · price: Each issued and outstanding share of common stock was, as a result of the consummation of the merger contemplated by the Agreement and Merger by and among CAS Medical Systems, Inc., Edwards Lifesciences Holding, Inc. and Crown Merger Sub, Inc., dated as of February 11, 2019 (the "Merger Agreement"), canceled in exchange for the right to receive a per share amount equal to $2.45 in cash without interest. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 10:13 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-18-000044 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,889 F1 · price: Restricted stock grant vesting in four equal annual installments from the date of grant. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 10:40 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001615774-18-012885 · s114047_form4.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-11-14 F1 · derivative.exercise_date: Option is exercisable in four equal annual installments from the date of grant. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:05 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-18-000014 · edgar.xml · nonDerivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,889 Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:05 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-18-000014 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980,889 F1 · price: Restricted stock grant vesting in three equal annual installments on 8/1/19, 8/1/20 and 8/1/21. Read SEC document |
| May 17, 2018 Filed May 18, 2018 16:18 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | OtherCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-18-000008 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Relative's IRA Disclosed balance after: 0 F1 · shares: Mr. Patton no longer holds voting or dispositive power over the relative's IRA. No market transaction occurred. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 09:24 UTC | MISONIX INC MSON · Entity 132701 | PurchaseCommon Stock | 1,000 | $10.05 | $10,050.00 |
DisclosureSEC source: 0001615774-18-001231 · s109064_form4.xml · nonDerivative · entry 4 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 09:24 UTC | MISONIX INC MSON · Entity 132701 | PurchaseCommon Stock | 1,300 | $10.25 | $13,325.00 |
DisclosureSEC source: 0001615774-18-001231 · s109064_form4.xml · nonDerivative · entry 3 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 09:24 UTC | MISONIX INC MSON · Entity 132701 | PurchaseCommon Stock | 2,200 | $10.25 | $22,539.00 |
DisclosureSEC source: 0001615774-18-001231 · s109064_form4.xml · nonDerivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 09:24 UTC | MISONIX INC MSON · Entity 132701 | PurchaseCommon Stock | 500 | $10.15 | $5,075.00 |
DisclosureSEC source: 0001615774-18-001231 · s109064_form4.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 14:13 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001449374-17-000045 · edgar.xml · derivative · entry 3 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-12-21 F2 · derivative.exercise_date: Stock option vesting in four equal annual installments on 12/21/18, 12/21/19, 12/21/20 and 12/21/21. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 14:13 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-17-000045 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,889 F1 · price: Restricted stock grant vesting in four equal annual installments on 12/21/18, 12/21/19, 12/21/20 and 12/21/21. Read SEC document |
| December 21, 2017 Filed Jan 2, 2018 10:58 UTC Amendment | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001449374-18-000002 · edgar.xml · derivative · entry 3 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-12-21 F2 · derivative.exercise_date: Stock option vesting in four equal annual installments on 12/21/18, 12/21/19, 12/21/20 and 12/21/21. Read SEC document |
| December 21, 2017 Filed Jan 2, 2018 10:58 UTC Amendment | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-18-000002 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,889 F3 · shares: Corrects grant amount from previous filing. F1 · price: Restricted stock grant vesting in four equal annual installments on 12/21/18, 12/21/19, 12/21/20 and 12/21/21. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 16:06 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0001615774-17-004566 · s107240_form4.xml · derivative · entry 2 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-08-16 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 16:06 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0001615774-17-004566 · s107240_form4.xml · derivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-08-16 Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 12:28 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 74,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001571049-17-002381 · t1700732_x1.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,889 Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 10:14 UTC | CAS MEDICAL SYSTEMS INC CASM · Entity 158232 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001449374-17-000013 · edgar.xml · nonDerivative · entry 1 PATTON THOMAS M · CIK 0001310306 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,677 F1 · price: Restricted stock grant vesting in four equal annual installments on 1/9/18, 1/9/19, 1/9/20 and 1/9/21. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.